HPTN 091: Integrating HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation for Transgender Women in the Americas: A Vanguard Study
Study to Help Transgender Women use HIV Prevention Services Effectively
Enrolling: Female Patients Only
Study Length: 18 Months
Clinic Visits: 8
IRB Number: AAAT5172
U.S. Govt. ID: NCT04742491
Contact: Nora Howell: 347-841-4285 / hpcresearch@cumc.columbia.edu
Additional Study Information: We are conducting a study to see if offering pre-exposure prophylaxis (PrEP) together with another health service that many transgender women use or would like to use, gender-affirming hormone therapy (GAHT), improves HIV-related outcomes, as compared to offering PrEP and referring study participants to get GAHT at area health providers. This study is for adults who were assigned male at birth and who currently identify themselves as women, transgender women, women of the trans experience, or along a trans-feminine spectrum; are sexually active, and HIV-negative. Everyone participating will be offered PrEP at the study center. Study participants will also have access to GAHT. If you are eligible for the study and decide to enroll, you will be compensated up to $75 for each of eight scheduled study visits. At each visit you will be asked to provide blood samples; at some visits, you will also be asked to provide samples to test for sexually transmitted infections. Thank you for your ongoing support of HIV prevention research in New York!
This study is closed
Julie Franks, PhD
Do You Qualify?
Are you at least 18 years old? Yes No
Are you a transgender woman (assigned male at birth and of the trans-feminine experience)? Yes No
Are you HIV-negative? Yes No
Are you planning to stay in the New York City area for the next 18 months? Yes No
Are you okay with having your blood drawn? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Nora Howell